Evolus, Inc. (NASDAQ:EOLS – Get Rating) insider David Moatazedi sold 64,211 shares of Evolus stock in a transaction that occurred on Tuesday, March 14th. The stock was sold at an average price of $8.47, for a total value of $543,867.17. Following the sale, the insider now owns 615,677 shares in the company, valued at $5,214,784.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Evolus Stock Down 1.4 %
EOLS stock opened at $8.37 on Friday. The firm has a market cap of $472.15 million, a price-to-earnings ratio of -6.34 and a beta of 1.93. Evolus, Inc. has a 1-year low of $6.51 and a 1-year high of $14.34. The firm has a fifty day moving average price of $9.26 and a two-hundred day moving average price of $8.53. The company has a debt-to-equity ratio of 3.89, a current ratio of 2.17 and a quick ratio of 1.76.
Wall Street Analyst Weigh In
EOLS has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Evolus in a research note on Thursday, March 9th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Evolus in a research report on Thursday, March 9th. SVB Leerink upped their target price on shares of Evolus from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, January 19th. Finally, Mizuho lifted their price target on Evolus from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, January 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.00.
Institutional Inflows and Outflows
Evolus Company Profile
Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.